We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Alliance Develops Tests for Food-Borne Pathogens

By Labmedica staff writers
Posted on 01 Jul 2003
Five new lateral flow rapid tests for food-borne pathogens have been jointly developed by BBInternational (BBI, Cardiff, UK) and the Analytics & Reagents Division of Merck KgaA (Darmstadt, Germany).

The five tests developed are for E Coli 0157, Salmonella, Campylobacter, Listeria, and Verotoxin type 1 and 2. The tests allow detection in less than 20 minutes and can reliably guarantee the absence of the five important pathogens. Lateral flow tests are becoming more popular, because they provide a quick and reliable diagnosis. The new tests are based on BBI's expertise in lateral flow development and the production of premium gold colloid.

Merck identified the tests needed and then sought a technology platform that could produce them, finding one at BBI, which provides new-product development services for companies with limited lateral flow experience.

"It is an ideal choice for those who want to fully outsource the development of a new rapid test, including reagent development, without losing the ownership of how the test is developed and marketed,” said Julian Barnes, managing director of BBI. "Merck KgaA and BBI have worked together consistently over the last year and have developed five tests that both teams can be proud of.”


Related Links:
BBI
Merck

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
01 Jul 2003  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
01 Jul 2003  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
01 Jul 2003  |   Industry



PURITAN MEDICAL